CXC chemokines: the regulatory link between inflammation and angiogenesis.
暂无分享,去创建一个
Sergio Romagnani | M. Serio | F. Annunziato | P. Romagnani | S. Romagnani | Paola Romagnani | Francesco Annunziato | L. Lasagni | Mario Serio | Laura Lasagni
[1] A. Wells,et al. Glu-Leu-Arg-negative CXC chemokine interferon gamma inducible protein-9 as a mediator of epidermal-dermal communication during wound repair. , 2003, The Journal of investigative dermatology.
[2] D. Markovitz,et al. Interleukin-8 and Growth-Regulated Oncogene Alpha Mediate Angiogenesis in Kaposi's Sarcoma , 2002, Journal of Virology.
[3] R. Strieter,et al. CXC chemokines in angiogenesis related to pulmonary fibrosis. , 2002, Chest.
[4] E Lazzeri,et al. Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) alphabeta+ CD8+ single-positive T cells, TCRgammadelta+ T cells, and natural killer-type cells in hum , 2001, Blood.
[5] A. Wells,et al. Ip-10 Inhibits Epidermal Growth Factor–Induced Motility by Decreasing Epidermal Growth Factor Receptor–Mediated Calpain Activity , 1999, The Journal of cell biology.
[6] M. Iannettoni,et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. , 1998, The Journal of clinical investigation.
[7] M. Burdick,et al. Enhanced tumor‐forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth‐regulated cytokine β and γ proteins , 1997 .
[8] D. Kolson,et al. CXCR3 expression in human central nervous system diseases , 2001, Neuropathology and applied neurobiology.
[9] S. Nishikawa,et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.
[10] P. Libby,et al. Differential Expression of the IFN-γ-Inducible CXCR3-Binding Chemokines, IFN-Inducible Protein 10, Monokine Induced by IFN, and IFN-Inducible T Cell α Chemoattractant in Human Cardiac Allografts: Association with Cardiac Allograft Vasculopathy and Acute Rejection1 , 2002, The Journal of Immunology.
[11] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[12] M. Volin,et al. Chemokine receptor CXCR4 expression in endothelium. , 1998, Biochemical and biophysical research communications.
[13] P. Allavena,et al. Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.
[14] G Bernardini,et al. The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. , 2001, Biochemical and biophysical research communications.
[15] S. Narula,et al. Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. , 2001, Cytokine.
[16] J. Sedgwick,et al. Tumor Necrosis Factor–dependent Segmental Control of MIG Expression by High Endothelial Venules in Inflamed Lymph Nodes Regulates Monocyte Recruitment , 2001, The Journal of experimental medicine.
[17] G. Gray,et al. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. , 1991, Cancer research.
[18] L. Luistro,et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.
[19] M. Serio,et al. Signal Transduction by the Chemokine Receptor CXCR3 , 2001, The Journal of Biological Chemistry.
[20] E. Rofstad,et al. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. , 2000, Cancer research.
[21] M. Goebeler,et al. Chemokines in cutaneous wound healing , 2001, Journal of leukocyte biology.
[22] A. Griffioen,et al. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.
[23] R. Salcedo,et al. Role of Chemokines in Angiogenesis: CXCL12/SDF‐1 and CXCR4 Interaction, a Key Regulator of Endothelial Cell Responses , 2003, Microcirculation.
[24] P. Leder,et al. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation , 1995, The Journal of experimental medicine.
[25] J. Norgauer,et al. Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. , 1996, Journal of immunology.
[26] Claudio Ronco,et al. Blood and dialysate flow distributions in hollow-fiber hemodialyzers analyzed by computerized helical scanning technique. , 2002, Journal of the American Society of Nephrology : JASN.
[27] H. Nomiyama,et al. Chemokines in immunity. , 2001, Advances in immunology.
[28] J. Finke,et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.
[29] D. Ribatti,et al. Analysis of the role of chemokines in angiogenesis. , 2003, Journal of immunological methods.
[30] A. Zlotnik,et al. The biology of chemokines and their receptors. , 2000, Annual review of immunology.
[31] R. Schreiber,et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.
[32] Simon A. Jones,et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.
[33] I. Katz,et al. Platelet Factor 4: Production, Structure, and Physiologic and Immunologic Action , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[34] Erwin G. Van Meir,et al. Upregulation of Interleukin 8 by Oxygen-deprived Cells in Glioblastoma Suggests a Role in Leukocyte Activation, Chemotaxis, and Angiogenesis , 1997, The Journal of experimental medicine.
[35] A. Zlotnik,et al. Chemokines: a new classification system and their role in immunity. , 2000, Immunity.
[36] J. Teruya-Feldstein,et al. Contribution of the CXC chemokines IP‐10 and Mig to the antitumor effects of IL‐12 , 1998, Journal of leukocyte biology.
[37] P. Wen,et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth , 1997, Nature Medicine.
[38] K. Takeda,et al. Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. , 1996, Journal of immunology.
[39] A. Bikfalvi,et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. , 1999, Blood.
[40] C. Caux,et al. Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms1 , 2000, The Journal of Immunology.
[41] G. Gentilini,et al. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). , 1999, Blood.
[42] A. Richmond,et al. Delayed wound healing in CXCR2 knockout mice. , 2000, The Journal of investigative dermatology.
[43] M. Bryckaert,et al. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. , 2002, Blood.
[44] K. Fung,et al. Expression Pattern of CXCR3, CXCR4, and CCR3 Chemokine Receptors in the Developing Human Brain , 2001, Journal of neuropathology and experimental neurology.
[45] M. Sticherling,et al. Bioactive interleukin-8 is expressed in wounds and enhances wound healing. , 2000, The Journal of surgical research.
[46] M. Serio,et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.
[47] S. Werner,et al. Regulation of wound healing by growth factors and cytokines. , 2003, Physiological reviews.
[48] J. Teruya-Feldstein,et al. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo , 1997 .
[49] G. Neufeld,et al. Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms (*) , 1995, The Journal of Biological Chemistry.
[50] H. Kleinman,et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. , 1999, The American journal of pathology.
[51] E. Hudson,et al. Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[52] T. Yue,et al. Interferon-inducible Protein-10 Involves Vascular Smooth Muscle Cell Migration, Proliferation, and Inflammatory Response* , 1996, The Journal of Biological Chemistry.
[53] F. C. Lucibello,et al. Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. , 1995, The EMBO journal.
[54] Kouji Matsushima,et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.
[55] B. Evers,et al. Inflammation and the development of pancreatic cancer. , 2002, Surgical oncology.
[56] D. Tatakis. Human platelet factor 4 is a direct inhibitor of human osteoblast-like osteosarcoma cell growth. , 1992, Biochemical and biophysical research communications.
[57] Sergio Romagnani,et al. An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 , 2003, The Journal of experimental medicine.
[58] P. Hansell,et al. Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. , 1995, The American journal of physiology.
[59] H. Moch,et al. Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.
[60] P. Leder,et al. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.
[61] A. Zlotnik,et al. Chemokines: agents for the immunotherapy of cancer? , 2002, Nature Reviews Immunology.
[62] H. Augustin,et al. Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. , 1998, Biochemical and biophysical research communications.
[63] A. Angiolillo,et al. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.
[64] M. Salvadori,et al. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. , 1999, Journal of the American Society of Nephrology : JASN.
[65] L. Adorini,et al. Cutting Edge: Selective Usage of Chemokine Receptors by Plasmacytoid Dendritic Cells1 , 2001, The Journal of Immunology.
[66] L. Coussens,et al. Inflammation and cancer , 2002, Nature.
[67] J. Isner,et al. Stromal Cell–Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell Recruitment for Ischemic Neovascularization , 2003, Circulation.
[68] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[69] M. Parmentier,et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. , 2001, Blood.
[70] R. Gamelli,et al. Modulation of macrophage recruitment into wounds by monocyte chemoattractant protein‐1 , 2001, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[71] T. Springer,et al. The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood , 1997, The Journal of experimental medicine.
[72] M. Huising,et al. Molecular evolution of CXC chemokines: extant CXC chemokines originate from the CNS. , 2003, Trends in immunology.
[73] T. Springer,et al. Expression of Stromal-Derived Factor-1 Is Decreased by IL-1 and TNF and in Dermal Wound Healing1 , 2001, The Journal of Immunology.
[74] J. Teruya-Feldstein,et al. Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12 , 1999 .
[75] C. Caux,et al. Chemokines in cancer. , 2002, Cytokine & growth factor reviews.
[76] Franklin Peale,et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium , 2001, Nature.
[77] D. Remick,et al. Interleukin‐8 levels and activity in delayed‐healing human thermal wounds , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[78] L. Kemény,et al. Role of interleukin-8 receptor in skin. , 1994, International archives of allergy and immunology.
[79] E. Bröcker,et al. Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. , 1998, The American journal of pathology.
[80] R. Derynck,et al. Effects of MGSA/GRO alpha on melanocyte transformation. , 1991, Oncogene.
[81] M. Burdick,et al. The CXC Chemokine Receptor 2, CXCR2, Is the Putative Receptor for ELR+ CXC Chemokine-Induced Angiogenic Activity1 , 2000, The Journal of Immunology.
[82] M. Shuman,et al. Thrombin generation and secretion of platelet Factor 4 during blood clotting. , 1978, The Journal of clinical investigation.